Výsledky vyhledávání - "Adam J. Camblin"

Data from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

Purpose: Insulin-like growth factor receptor 1 (IGF-1R) is critically involved in pancreatic cancer pathophysiology, promoting cancer cell survival and therapeutic resistance. Assessment of IGF-1R inhibitors in combination with standard-of-care chemo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67565d75c08617bb5e48fee4d51b15c3
https://doi.org/10.1158/1078-0432.c.6526055.v1

Zobrazit plný text záznamu

Figure S1 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

Supplemental Figure S1: IGF-1 and HRG induce strongest AKT phosphorylation in pancreatic cancer cells.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e60819117dd02fcb2502c593cb58ab3
https://doi.org/10.1158/1078-0432.22465559.v1

Zobrazit plný text záznamu

Figure S3 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

Supplemental Figure S3: Istiratumab induces ubiquitination of IGF-1R and ErbB3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77f94e5c08d2d62ef354404ddcade93
https://doi.org/10.1158/1078-0432.22465553.v1

Zobrazit plný text záznamu

Figure S4 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

Supplemental Figure S4: Istiratumab restores activity of chemotherapy in the presence of IGF-1 and HRG.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bf15d54ea004ca3649c341eb8eb0908
https://doi.org/10.1158/1078-0432.22465550

Zobrazit plný text záznamu

Table S1 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

Table S1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f42cbe77298eae397c79869e3f6871f
https://doi.org/10.1158/1078-0432.22465535.v1

Zobrazit plný text záznamu

Supplemental legend from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

Supplemental legend

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54f3bcbb0f2da6bc498d87084abe5f06
https://doi.org/10.1158/1078-0432.22465538.v1

Zobrazit plný text záznamu

Table S2 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

Table S2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73049f64a884b0c0c46b5940562de702
https://doi.org/10.1158/1078-0432.22465532

Zobrazit plný text záznamu

Abstract 555: A novel human TNFR2 antibody (MM-401) modulates T cell responses in anti-cancer immunity

Autor: James F. Sampson, Vinodh B. Kurella, Violette Paragas, Sandeep Kumar, James E. Lulo, James A. Qiu, Maja Razlog, Ross B. Fulton, Adam J. Camblin, Jennifer M. Richards, Christina S. Wong, Alexander Koshkaryev, James J. Suchy, Stephanie Grabow, Marco Muda, Andreas Raue, Daryl C. Drummond, Eric M. Tam

Publikováno v: Cancer Research. 79:555-555

TNFR2 is an emerging therapeutic target in immuno-oncology. We have previously shown that an agonistic mouse TNFR2 antibody was able to activate CD8+ T cells in vitro and has anti-tumor activity in multiple syngeneic mouse tumor models. This activity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4c9f14a39bb58f6cf7c277d0e6b2529a
https://doi.org/10.1158/1538-7445.am2019-555

Zobrazit plný text záznamu

A novel TNFR2 antibody induces T cell co-stimulation and promotes durable anti-tumor immunity

Publikováno v: The Journal of Immunology. 202:195.11-195.11

TNFR2, an emerging therapeutic target in immuno-oncology, is upregulated upon T cell activation and is expressed by tumor-infiltrating effector and regulatory T (Treg) cells. We generated a novel monoclonal antibody, Y9, specific to murine TNFR2 and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::624e86a920e0d2baffd92d61cd0d3ecf
https://doi.org/10.4049/jimmunol.202.supp.195.11

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání